Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01301521 · ClinicalTrials.gov registry record · NA
Cinnamon Trial-lIfestyle iNtervention Plus Water-soluble Cinnamon Extract On loweriNg Blood Glucose in Pre-diabetics
A NA study, sponsored by Mike O'Callaghan Military Hospital.
- Completed
- Registry status
- NA
- Development phase
- 229
- Enrollment target
NCT01301521: Completed NA study, sponsored by Mike O'Callaghan Military Hospital.
NCT01301521 is a NA study that has completed, run by Mike O'Callaghan Military Hospital. The registered enrollment target is 229 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01301521, a NA study, has completed, sponsored by Mike O'Callaghan Military Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 229 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether water-soluble cinnamon extract plus aggressive lifestyle intervention is effective in lowering blood glucose in pre-diabetic patients when compared to aggressive lifestyle therapy plus placebo.
Primary Outcome
Does water-soluble cinnamon extract delay the onset of diabetes or extend the time to diagnosis of diabetes in pre-diabetic patients who are already undergoing aggressive lifestyle therapy?
Interventions
- DRUG water-soluble cinnamon extract (Cinnulin PF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2013-06-11 |
| Est. Completion | 2019-04-26 |
| Phase | NA |
What the finished NCT01301521 record still lists
NCT01301521 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 1 intervention - of which water-soluble cinnamon extract (Cinnulin PF) is the first listed.
NCT01301521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01301521 about?
NCT01301521 is a clinical study titled "Cinnamon Trial-lIfestyle iNtervention Plus Water-soluble Cinnamon Extract On loweriNg Blood Glucose in Pre-diabetics". The purpose of this study is to assess whether water-soluble cinnamon extract plus aggressive lifestyle intervention is effective in lowering blood glucose in pre-diabetic patients when compared to aggressive lifestyle therapy plus placebo.
What is the current status of trial NCT01301521?
This trial is currently completed. It is a NA study. The enrollment target is 229 participants. The study started on 2013-06-11. Estimated completion is 2019-04-26.
What interventions are being tested in trial NCT01301521?
The interventions under investigation include: water-soluble cinnamon extract (Cinnulin PF) (DRUG).
Who is sponsoring clinical trial NCT01301521?
This trial is sponsored by Mike O'Callaghan Military Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01301521's enrollment target sits among peer trials
229 468th of 2000 higher than 1,533 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI